Advances in hyperarathyroidism: Pathogenesis and treatment - Introduction: emerging therapies derived from the molecular pathogenesis of secondary hyperparathyroidism in ESRD patients

被引：1
|
作者：
Quarles, LD
机构：
来源：
ADVANCES IN RENAL REPLACEMENT THERAPY | 2002年 / 9卷 / 03期
关键词：
D O I：
10.1053/jarr.2002.34839
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：153 / 158
页数：6
相关论文
共 4 条
  • [1] Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: The role of paricalcitol
    Cozzolino, Mario
    Galassi, Andrea
    Gallieni, Maurizio
    Brancaccio, Diego
    CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (02) : 148 - 153
  • [2] Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021
    Falanga, Anna
    Brenner, Benjamin
    Khorana, Alok A.
    Francis, Charles W.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (05)
  • [3] Understanding the Molecular Pathogenesis of and Response to Canakinumab Treatment in TNF Receptor-Associated Periodic Syndrome By Gene Expression Profiling of Whole Blood from Patients
    Torene, R.
    Gattorno, M.
    Lachmann, H.
    Obici, L.
    Meini, A.
    Tormey, V.
    Caorsi, R.
    Baeriswyl, L.
    Affentranger, U.
    Starck-Schwertz, S.
    Letzkus, M.
    Hartmann, N.
    Abrams, K.
    Nirmala, N.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S130 - S131
  • [4] Multifactorial pathogenesis of cancer associated venous thrombosis: Results from the baseline profiling of cancer patients recruited in a study for the secondary prevention of venous thrombosis with a low molecular weight heparin (ONCENOX).
    Fareed, J
    Hoppensteadt, D
    Kahn, S
    Bermes, E
    Tobu, M
    Cort, S
    Deitcher, S
    CLINICAL CHEMISTRY, 2003, 49 (06) : A9 - A10
1